Medical News

RSS

HealthSouth plans new rehabilitation hospital in northwest Houston

HealthSouth Corporation today announced plans to begin construction of a new 40-bed inpatient rehabilitation hospital in the Cypress area of northwest Houston in the fourth quarter. In connection with such plans, HealthSouth has signed a contract to purchase a 6-acre tract of land from an affiliate of Caldwell Companies, based in Houston. The land is located on the northeast corner of Highway 290 and FM 1960 in Houston.

31 Jul 2010

Patients with malignant gastrointestinal disease show high prevalence of malnutrition

Malnutrition is an important factor, influencing both morbidity and recovery after surgery. The early detection of nutritional risk would allow early intervention, which may prevent later complications. A traditional nutritional assessment often includes dietary and medical evaluations to identify significant weight loss over time, significantly low or high body weight(BW), skinfold thickness, serum nutritional factor levels and functional measurements of muscle strength.

31 Jul 2010

Researchers receive $4.7M contract to develop drugs to improve soldiers' performance at high altitude

Jonathan Stamler, MD, Director of the Institute for Transformative Molecular Medicine and the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation at the Case Western Reserve University and University Hospitals Harrington-McLaughlin Heart & Vascular Institute, has recently received a $4.7 million contract from the Defense Advanced Research Projects Agency to fund the development of a new class of drugs that will selectively dilate blood cells under hypoxia (lack of oxygen in the body's tissues) and thereby enhance soldiers' performance at high altitude.

31 Jul 2010

Blumenthal defends hew health IT rules to Utah leaders

David Blumenthal, the national coordinator for health information technology for the U.S. Department of Health and Human Services, "defended the administration's new plans against critics who say the watered-down rules miss an opportunity to lower costs and improve patient care," The Salt Lake Tribune reports.

31 Jul 2010

Galangin mediates apoptosis of hepatocellular carcinoma cells through mitochondrial pathway: Study

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, particularly in China. However, HCC remains one of the more difficult cancers to treat. It is important to screen for new anti-cancer drugs. A number of dietary compounds possess anti-cancer properties. These dietary compounds may modify the activity of specific targets that control cell proliferation and apoptosis. Galangin could inhibit the methoxyresorufin O-demethylase activity of CYP1A2, CYP1A1 and P-form phenolsulfotransferase.

31 Jul 2010

Abortion rights supporters, children's groups, GOP pushing back on various health law provisions

"Elective abortions will be prohibited and people with pre-existing conditions will be able to get comprehensive benefits without paying any more than healthy people, under new federal regulations for high-risk health insurance pools released ... by the Obama administration," according to Kaiser Health News.

31 Jul 2010

Study finds ST131 a major cause of antimicrobial-resistant E. coli infections

The new strain, ST131, was a major cause of serious antimicrobial-resistant E. coli infections in the United States in 2007, researchers found. This strain has been reported in multiple countries and encountered all over the United States. In the study, researchers analyzed resistant E. coli isolates collected during 2007 from hospitalized patients across the country. They identified 54 ST131 isolates, which accounted for 67 percent to 69 percent of E. coli isolates exhibiting fluoroquinolone or extended-spectrum cephalosporin resistance.

31 Jul 2010

Resveratrol suppresses inflammation in humans: Research

Resveratrol, a popular plant extract shown to prolong life in yeast and lower animals due to its anti-inflammatory and antioxidant properties, appears also to suppress inflammation in humans, based on results from the first prospective human trial of the extract conducted by University at Buffalo endocrinologists.

31 Jul 2010

Water Street Healthcare Partners acquires Medical Specialties Distributors

Water Street Healthcare Partners, a leading private equity firm focused exclusively on health care, announced today that it has acquired Medical Specialties Distributors, LLC (MSD). Headquartered in Stoughton, Massachusetts, MSD is the nation's leading provider of infusion products, supplies, biomedical services and technology solutions to the growing home infusion therapy market. The acquisition expands Water Street's current group of health care companies to 12.

From Baxter International Inc. 31 Jul 2010

Measuring GAPDH inhibiting antibodies can result in long-term treatment for MS

UCI immunologists have found that testing for increased levels of antibodies that inhibit energy production in neurons can detect axon and neuron degeneration in multiple sclerosis earlier than existing diagnostic tools.

31 Jul 2010

The House fails to pass aid measure for sick 9/11 responders

The Associated Press: "A bill that would have provided up to $7.4 billion in aid to people sickened by World Trade Center dust fell short in the House on Thursday, raising the possibility that the bulk of compensation for the ill will come from a legal settlement hammered out in the federal courts." The measure failed to draw the necessary two-thirds majority. Democrats had opted for this procedural route rather than a simple majority because it blocked potential GOP amendments.

31 Jul 2010

Researchers suggest soybean isoflavones enhance bone health

Scientists already know much about the more than 200 bones that make up your body. But mysteries remain regarding the exact role that many natural compounds in foods might play in strengthening our skeletons. Those compounds include estrogen-like substances known as soybean isoflavones.

31 Jul 2010

Vitacost.com second-quarter net sales increase 14% to $54.0 million

Vitacost.com, Inc., a leading online retailer and direct marketer of health and wellness products, today reported preliminary financial results for the second quarter ended June 30, 2010.

31 Jul 2010

Scientists identify enzyme to prevent beta-amyloids formation in Alzheimer patients

The brains of Alzheimer patients have high accumulations of the material beta-amyloid, which appear in the form of plaques. The precursors of these plaques are believed to be the underlying cause of the nerve cell loss that leads to the disruptions in memory that characterize Alzheimer's disease. The main aim of many Alzheimer therapies is therefore to inhibit the formation of beta-amyloid. Since beta-amyloid is cleaved from the so-called amyloid precursor protein (APP), scientists have focused on stopping the two enzymes that attack the precursor protein. These act like molecular scissors and cut out the beta-amyloid fragment. Blocking these scissors precludes the formation of beta-amyloid.

31 Jul 2010

CD74 can serve as prognostic marker for colorectal cancer

CD74 is a protein that is expressed in and on cells of the immune system, such as B lymphocytes and antigen presenting cells. This protein is known for its function in facilitating antigen presentation enabling the immune response. Additionally, Professor Shachar's lab has previously shown that CD74 serves as a survival receptor on cells of the immune system, and that its stimulation by its natural ligand -migration inhibitory factor (MIF)- prevents apoptosis (self destruction) of these cells. It was shown that CD74 is markedly expressed on numerous tumors - hematologic as well as epithelial, and can serve as a prognostic marker. CD74's expression and function on colon intestinal epithelial cells is controversial.

31 Jul 2010

Lundbeck voluntarily recalls two lots of NeoProfen Injection

Lundbeck Inc. has voluntarily recalled two lots of NeoProfen® (ibuprofen lysine) Injection that failed to meet a visible particulate quality requirement. These two lots are the only lots currently available to prescribers and therefore the recall will result in a temporary drug shortage. This voluntary recall is the result of the company's inspections of the two product lots of NeoProfen.

31 Jul 2010

Adequate calcium intake maintains optimum bone mass

A broad range of scientific research has demonstrated that an adequate intake of calcium plays an important role in building and maintaining optimum bone mass, and a recent meta-analysis published online in the British Medical Journal should not cause consumers to doubt the value of calcium supplements for maintaining bone health.

31 Jul 2010

Northstar plans non-brokered private placement of common shares to Canada Healthcare Acquisition

Northstar Healthcare Inc. today announced that it plans to complete a non-brokered private placement of common shares to Canada Healthcare Acquisition Inc., a corporation indirectly controlled by Dr. Donald L. Kramer, M.D., a former CEO and former director of Northstar.

31 Jul 2010

QPharma releases qSpend Web-based aggregate spend solution

QPharma, Inc., the industry leader in FDA Regulatory and Compliance Solutions, announced today the official release of their aggregate spend solution, qSpend. This tool assists Pharmaceutical, Biotechnology, and Medical Device companies in complying with countless state and federal laws, regulations, and industry guidelines governing sales and marketing. qSpend is QPharma's cost-efficient, aggregate spend solution for tracking, evaluating, and reporting sales and marketing expenditures in a regulatory compliant manner.

31 Jul 2010

AMP conducts survey on Genetic Test Registry

Today, the Association for Molecular Pathology (AMP) submitted written comments in response to the Request for Information made by the National Institutes of Health (NIH) for its Genetic Test Registry (GTR). AMP conducted a survey of its membership to formulate a comprehensive response to the RFI. "With the vast majority of respondents working in a clinical laboratory setting, AMP is able to inform the NIH on the general reaction to the GTR, including insight to the community's concerns and guidance to ensure the GTR is a valued resource," said Dr. Karen Mann, President of AMP.

31 Jul 2010